Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA17
MA17 Details
Status: Closed 
Activation Date: 1998AUG24
Closing Date: 2002SEP04
Phase: III 

Description: A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen 

Eligibility: Post-menopausal women who had receptor-positive breast cancer, or unknown receptor status breast cancer, and have completed at least five years of adjuvant tamoxifen therapy. 

Objective: To compare disease-free survival and overall survival. To compare incidence of contralateral breast cancer, and long-term clinical and laboratory safety. To evaluate overall quality of life. 

Participation: Open to centres in participating cooperative groups. 

Lay Description: The purpose of this study is to find out whether it is better to receive letrozole or no further treatment after stopping tamoxifen. To do this, half of the patients in the study will receive letrozole and the other half will receive a placebo (a preparation with no active substance of medicinal value). Treatment with letrozole or placebo will begin within three months of tamoxifen being stopped. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
BREAST MA17 5187 873 284 1081
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
BREAST MA17 5187 1 23
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
BREAST MA17 5187 0 0 0 0 0 0 0 0